A review of multiple endocrine adenomas type 1 associated parathyroid tumors

doi:10.3877/cma.j.issn.1674-0793.2022.02.014

Abstract

Abstract:

Multiple endocrine neoplasia type 1 (MEN-1), an autosomal dominant genetic disease, often has multiple neoplasms and produces a series of endocrine syndromes. In MEN-1 patients, primary hyperparathyroidism from parathyroid tumors is often the initial presentation of the syndrome. This article reviews the studies on MEN-1-related parathyroid tumors.

Key words: Multiple endocrine neoplasia type 1, Primary hyperparathyroidism, Gene screening, Parathyroidism surgery, Familial isolated hyperparathyroidism

Wei Yan, Qingjun Gao, Kangyan Yang, Rongjun Gao, Ying Peng, Xu Dai, Jing Huang, Na Xiao, Hui Ye. A review of multiple endocrine adenomas type 1 associated parathyroid tumors[J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(02): 151-154.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2022.02.014

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2022/V16/I02/151

References 29

[1]	Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)[J]. J Clin Endocrinol Metab, 2012, 97(9): 2990-3011.
[2]	Lodewijk L, Bongers PJ, Kist JW, et al. Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1[J]. Eur J Endocrinol, 2015, 172(4): 337-342.
[3]	Niederle B, Selberherr A, Bartsch DK, et al. Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome - An international consensus statement[J]. Neuroendocrinology, 2021, 111(7): 609-630.
[4]	Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)[J]. Mol Cell Endocrinol, 2014, 386(1-2): 2-15.
[5]	Frederiksen A, Rossing M, Hermann P, et al. Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases[J]. J Clin Endocrinol Metab, 2019, 104(9): 3637-3646.
[6]	Marini F, Giusti F, Iantomasi T, et al. Parathyroid tumors: molecular signatures[J]. Int J Mol Sci, 2021, 22(20): 11206.
[7]	Kong J, Wang O, Nie M, et al. The expression of p27Kip1 and β-catenin in multiple endocrine neoplasia type 1-related parathyroid tumors[J]. Zhonghua Nei Ke Za Zhi, 2016, 55(11): 859-862.
[8]	Marx SJ, Goltzman D. Evolution of our understanding of the hyperparathyroid syndromes: A historical perspective[J]. J Bone Miner Res, 2019, 34(1): 22-37.
[9]	Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy[J]. Cell, 2012, 150(1): 12-27.
[10]	Donati S, Ciuffi S, Marini F, et al. Multiple endocrine neoplasia type 1: the potential role of microRNAs in the management of the syndrome[J]. Int J Mol Sci, 2020, 21(20): 7592.
[11]	Marx SJ. New concepts about familial isolated hyperparathy-roidism[J]. J Clin Endocrinol Metab, 2019, 104(9): 4058-4066.
[12]	Hackeng WM, Dreijerink KMA, Offerhaus GJA, et al. A parathyroid-gut axis: hypercalcemia and the pathogenesis of gastrinoma in multiple endocrine neoplasia 1[J]. Mol Cancer Res, 2021, 19(6): 946-949.
[13]	Liu P, Vakharia N, Zacharia A, et al. Bilateral giant parathyroid adenoma in the absence of multiple endocrine neoplasia type 1[J]. Ann R Coll Surg Engl, 2020, 102(6): e111-e114.
[14]	Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: A 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines[J]. J Clin Endocrinol Metab, 2015, 100(4): 1568-1577.
[15]	Herath M, Parameswaran V, Thompson M, et al. Paediatric and young adult manifestations and outcomes of multiple endocrine neoplasia type 1[J]. Clin Endocrinol (Oxf), 2019, 91(5): 633-638.
[16]	Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database[J]. Endocrine, 2017, 58(2): 349-359.
[17]	Di Meo G, Sgaramella LI, Ferraro V, et al. Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome: case report and systematic literature review[J]. Clin Exp Med, 2018, 18(4): 585-593.
[18]	Versnick M, Popadich A, Sidhu S, et al. Minimally invasive parathyroidectomy provides a conservative surgical option for multiple endocrine neoplasia type 1-primary hyperparathyroidism[J]. Surgery, 2013, 154(1): 101-105.
[19]	Lairmore TC, Govednik CM, Quinn CE, et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1[J]. Surgery, 2014, 156(6): 1326-1335.
[20]	Tonelli F, Marcucci T, Fratini G, et al. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?[J]. Ann Surg, 2007, 246(6): 1075-1082.
[21]	Moyes VJ, Monson JP, Chew SL, et al. Clinical use of cinacalcet in MEN1 hyperparathyroidism[J]. Int J Endocrinol, 2010, 2010: 906163.
[22]	Filopanti M, Verga U, Ermetici F, et al. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly[J]. Eur J Endocrinol, 2012, 167(2): 157-164.
[23]	Del Prete M, Marotta V, Ramundo V, et al. Impact of cinacalcet hydrochloride in clinical management of primary hyperparath-yroidism in multiple endocrine neoplasia type 1[J]. Minerva Endocrinol, 2013, 38(4): 389-394.
[24]	Giusti F, Tonelli F, Brandi ML. Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?[J]. Clinics (Sao Paulo), 2012, 67 Suppl 1: 141-144.
[25]	Singh Ospina N, Thompson GB, Lee RA, et al. Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1[J]. J Clin Endocrinol Metab, 2015, 100(1): E87-E90.
[26]	Schreinemakers JM, Pieterman CR, Scholten A, et al. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: A systematic review[J]. World J Surg, 2011, 35(9): 1993-2005.
[27]	Waldmann J, López CL, Langer P, et al. Surgery for multiple endocrine neoplasia type 1-associated primary hyperparath-yroidism[J]. Br J Surg, 2010, 97(10): 1528-1534.
[28]	Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients[J]. World J Surg, 2010, 34(2): 249-255.
[29]	de Laat JM, van der Luijt RB, Pieterman CR, et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients[J]. BMC Med, 2016, 14(1): 182.

Please choose a citation manager

Content to export